Artrya develops AI software that analyses cardiac CT scans, selling subscriptions and per-scan fees to hospitals. At A$3.07 versus fair value A$0.80, the stock trades at nearly four times our assessment, driven by AI-healthcare enthusiasm disconnected from commercial reality. The company has converted only two of six contracted partnerships to revenue after 18 months, whilst burning A$5 million quarterly—a pattern suggesting hospital integration complexity is materially worse than management guidance implied.

Best fit: Thematic investors seeking AI-healthcare exposure. This is a speculative position on whether AI can penetrate hospital workflows despite integration complexity. The A$82.5 million cash position (A$1.04 per share) provides downside protection that pure-play development-stage companies lack. Investors must accept 50% probability of execution failure (requiring dilutive funding or M&A exit) and quarterly monitoring of partnership conversion velocity. Not suitable for income, value, or quality-focused portfolios given the 74% overvaluation and pre-profit profile.

Artrya sells AI software that analyses cardiac CT scans for coronary artery disease. Hospitals pay subscription fees (A$80,000-250,000 annually) plus per-scan charges (A$750 average) for three modules: Anatomy (structure analysis), Plaque (disease detection), and Flow (blood flow assessment). Revenue derives from cloud-based software, not equipment sales.

FY25 generated A$28,000 revenue from a single customer (Cardiac Centre NSW), whilst the company burned A$6.7 million. Two of six contracted partnerships are now live—Tanner Health System began generating revenue in mid-2025. Integration timelines have stretched materially: Sonic Healthcare and Lumus Imaging show 7-9 month delays post-contract signature with zero revenue disclosed. FDA clearances came through on schedule (Anatomy March 2025, Plaque August 2025), but commercial execution lags guidance.

The investment case centres on whether hospital integration complexity is temporary friction or structural barrier. Base case valuation (A$0.94 per share, 50% probability) assumes 4-5 partnerships convert by FY27 and profitability by FY30. Bear case (A$0.13, 35% probability) models sustained integration failures requiring dilutive funding. The cash position (A$82.5 million) provides tangible asset value independent of operational success. At A$3.07 versus fair value A$0.80, the stock is overvalued by 74%.

What happened?

FY25 delivered minimal revenue (A$28,000) from Cardiac Centre NSW, the company's inaugural customer. Tanner Health System commenced commercial operations mid-2025, contributing to the FY26 ramp. Two FDA clearances arrived on schedule—Anatomy (March) and Plaque (August)—validating the technology. However, four contracted partnerships remain in validation phases, with observable delays suggesting hospital IT integration requires 18-24 months versus management's implied 6-9 month guidance. Cash burn ran at A$5-6 million quarterly, funded by an A$80 million raise in September 2024.

What's next?

The trajectory depends entirely on partnership conversion velocity. Management targets three U.S. foundation partners (Tanner, NGHV, Cone Health) converting during FY26, but only one currently generates revenue. If conversions accelerate to 4-5 partnerships live by FY27, the base case (profitability by FY30, 22 customers terminal) becomes achievable. Flow module FDA submission is scheduled for late 2025, with clearance expected H1 2027—this adds a third revenue stream targeting 40% penetration of the Plaque customer base.

Key near-term catalysts: Q2 FY26 update (October 2025) will reveal whether NGHV and Cone Health have commenced revenue, validating or refuting the acceleration thesis. SAPPHIRE study enrollment pace (targeting 1,000 patients across 6-8 sites) provides clinical outcomes data by 2027, potentially strengthening pricing power. The cash runway extends 16 quarters at current burn rates, but the bear case requires dilutive funding by FY28 if commercialisation stalls.

Fair value of A$0.80 weights asset-based methods (55%) over DCF (5%) due to extreme terminal value dependency—the explicit forecast period burns A$35 million cumulatively, meaning the base case relies entirely on post-FY35 perpetuity assumptions. Cash of A$82.5 million provides A$1.04 per share, whilst FDA clearances and patents contribute A$0.19-0.38 per share in IP liquidation value. Transaction comparables (Subtle Medical A$40 million, Arterys A$55 million) validate strategic buyer interest in AI-cardiac assets.

The single biggest risk is partnership conversion failure. Only 33% of contracted partnerships generate revenue after 18 months. If this pattern persists—driven by hospital IT integration complexity (3-6 month PACS connectivity, 2-3 month clinician training) that management underestimated—the remaining four partnerships may never convert. Observable delays at Sonic Healthcare and Lumus Imaging (7-9 months post-contract, zero revenue) suggest systematic integration barriers, not isolated incidents. The bear scenario (35% probability) models just 2-3 of six partnerships ultimately converting, eliminating the profitability path and requiring A$40 million dilutive funding by FY28 at 40% equity dilution. This would compress fair value from A$0.80 to A$0.25 per share—a 69% loss. Quarterly partnership conversion monitoring is essential: if Q2 FY26 (October 2025) shows fewer than three partnerships live, execution failure probability rises materially.